Treatment details for participants in each cohort
| Trial | Mechanical thrombectomy cohort | IV r-tPA cohort | ||||||
| Treatment | n | Age (±SD) | Median NIHSS (IQR) | Treatment | n | Age (±SD) | Median NIHSS (IQR) | |
| MR CLEAN35 | ±IV r-tPA + MT ± (IA r-tPA or intra-arterial urokinase) | 233 | 65.8 (54.5–76)‡ | 17 (14–21) | ±IV r-tPA | 267 | 65.7 (55.5–76.4)‡ | 18 (14–22) |
| REVASCAT36* | ±IV r-tPA + M.T. | 103 | 65.7 (±11.3)¶ | 17 (14–20) | ±IV r-tPA | 103 | 67.2 (±9.5)¶ | 17 (12–19) |
| EXTEND 1A37† | IV r-tPA ± M.T. | 35 | 68.6 (±12.3)¶ | 17 (13–20) | IV r-tPA | 35 | 70.2 (±11.8)¶ | 13 (9–19) |
| SWIFT-prime38† | IV r-tPA ± M.T. | 98 | 65.0 (±12.5)¶ | 17 (13–20) | IV r-tPA | 98 | 66.3 (±11.3)¶ | 17 (13–19) |
| ESCAPE39† | M.T. ± IV r-tPA | 165 | 71 (60–81)‡ | 16 (13–20) | ±IV r-tPA | 150 | 70 (60–81)‡ | 17 (12–20) |
| THRACE40† | IV r-tPA ± M.T. | 200 | 66 (54–74)‡ | 18 (15–21) | IV r-tPA | 202 | 68 (54–75)‡ | 17 (13–20) |
| THERAPY41* | IV r-tPA ± M.T. | 55 | 67 (±11)¶ | 17 (13–22) | IV r-tPA | 53 | 70 (±10)¶ | 18 (14–22) |
| PISTE42 | IV r-tPA ± M.T. | 33 | 67 (±17)¶ | 18 (6–24)§ | IV r-tPA | 32 | 64 (±16)¶ | 14 (6–29)§ |
| EASI43* | IV r-tPA ± M.T. | 40 | 74 (62.7–80)‡ | 18 (13–21.75) | IV r-tPA | 37 | 71 (59–79)‡ | 20 (12–23) |
*Enrolment was halted early after positive results for thrombectomy were reported from other similar trials.
†Trial stopped early due to efficacy.
‡Median (IQR).
§Median (±range).
¶Mean (±SD).
IV r-tPA, intravenous recombinant tissue-type plasminogen activator; IA r-tPA, intra-arterial recombinant tissue-type plasminogen activator; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; SD, standard deviation.